Form 4: Halozyme Therapeutics CFO Receives Performance-Based Stock Units

Nicole LaBrosse, CFO of Halozyme Therapeutics, reports the acquisition of performance-based stock units that will vest based on continued service.

Summary

• Nicole LaBrosse, SVP and CFO of Halozyme Therapeutics, reported the acquisition of performance stock units (PSUs) on February 12, 2025.
• These PSUs were awarded on February 16, 2022, February 16, 2023, and February 23, 2024, with a performance measurement period ending December 31, 2024.
• The number of stock units that became eligible to vest was determined based on performance for the specified period.
• The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date.
• The reported transactions include the acquisition of 6,050, 5,221, 6,935 and 28,662 performance stock units.
• Following these transactions, LaBrosse directly owns 17,409, 8,184, 6,935 and 28,662 performance stock units respectively.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance and the executive's role in achieving it. It is a neutral to slightly positive event.

Positives

• The acquisition of performance-based stock units aligns the CFO's interests with the company's performance goals.
• The vesting schedule encourages continued service and commitment from the CFO.

Future Outlook

The CFO's stock units will vest based on continued service through the third anniversary of the grant date.

Industry Context

This filing is a routine disclosure of stock unit awards to a company executive, common in the biotechnology industry to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units to incentivize their executives.
• The specific terms of these grants, such as vesting schedules and performance metrics, vary from company to company.

Stakeholder Impact

• Shareholders may view the stock unit awards as a positive incentive for the CFO to drive company performance.
• Employees may see this as a sign of the company's commitment to its leadership team.

Next Steps

• The CFO will continue to fulfill the service-based requirements for the PSUs to vest.

Key Dates

Keywords

Halozyme Therapeutics, Nicole LaBrosse, CFO, Performance Stock Units, PSUs, Form 4, Beneficial Ownership, Equity Securities